MedTrace Logo

A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab

NCT02013154 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2025-08-03

No results posted yet for this study

Summary

A study to evaluate the safety and tolerability of DKN-01 in combination with weekly paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric Malignancies

Conditions

Interventions

DRUG

DKN-01 150 mg

Administered by IV infusion

DRUG

Paclitaxel

Administered by IV infusion

DRUG

Pembrolizumab

Administered by IV infusion

DRUG

DKN-01 300 mg

Administered by IV infusion

Sponsors & Collaborators

Principal Investigators

  • Cyndi Sirard, MD · Leap Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-05
Primary Completion
2019-07-19
Completion
2021-01-11

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02013154 on ClinicalTrials.gov